Replies to post #216858 on Biotech Values

[DewDiligence]

MNLO phase-2 for MTI-103 in pruritis/AD fails:

https://globenewswire.com/news-release/2018/04/08/1466633/0/en/Menlo-Therapeutics-Announces-Results-from-a-Phase-2-Trial-of-Serlopitant-for-Pruritus-Associated-with-Atopic-Dermatitis.html

Menlo Therapeutics…today announced top-line results from MTI-103 (ATOMIK), the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis (AD).

The study did not meet its primary or key secondary efficacy endpoints with no statistically significant difference demonstrated between the serlopitant treated groups and the placebo treated group. Numerical differences favoring the serlopitant treated group were evident at all timepoints.

CC tomorrow at 7am ET.